Peter Martin
MD
Associate Professor of Medicine
👥Biography 个人简介
Peter Martin has contributed foundational work on acalabrutinib, a second-generation BTK inhibitor, in relapsed and frontline MCL treatment, demonstrating improved tolerability compared to ibrutinib while maintaining efficacy. He led key studies evaluating BTK inhibitor-based induction regimens as alternatives to intensive chemoimmunotherapy in MCL. His research also addresses MCL epidemiology and outcomes in older patients.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Peter Martin 的研究动态
Follow Peter Martin's research updates
留下邮箱，当我们发布与 Peter Martin（Weill Cornell Medicine / NewYork-Presbyterian Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment